Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 3, 2015, Pages 220-226

  Weller, Karsten ^a   Zuberbier, Torsten ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

angioedema; disease activity; disease control; patient reported outcomes; quality of life; urticaria

Indexed keywords

ANGIONEUROTIC EDEMA; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CONSULTATION; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE CONTROL; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RECURRENT DISEASE; REVIEW; SELF REPORT; ANGIOEDEMA; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

ANGIOEDEMA; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; PRECISION MEDICINE; QUALITY OF LIFE; SELF REPORT;

EID: 84960096241     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000163     Document Type: Review

References (36)

1. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011; 66:317-330.
2. Weller K, Schoepke N, Krause K, et al. Selected urticaria patients benefit from a referral to tertiary care centres-results of an expert survey. J Eur Acad Dermatol Venereol 2013; 27:e8-e16.
3. Weller K, Viehmann K, Brautigam M, et al. Cost-intensive, time-consuming, problematical? How physicians in private practice experience the care of urticaria patients. J Dtsch Dermatol Ges 2012; 10:341-347.
4. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69:868-887.
5. Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol 2009; 160:633-641.
6. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9:69-80.
7. Mlynek A, Magerl M, Hanna M, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009; 64:927-936.
8. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
9. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132:101-109.
10. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368:924-935.
11. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73:57-62.
12. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omali-zumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135:67-75.
13. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60:1073-1078.
14. Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63:777-780.
15. Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133:1365-1372.
16. Weller K, Groffik A, Magerl M, et al. Development, construct validation of the angioedema Quality of Life Questionnaire (AE-QoL). Allergy 2012; 67:1289-1298.
17. Weller K, Groffik A, Magerl M, et al. Development, validation and initial results of the angioedema activity score (AAS). Allergy 2013; 68:1185-1192.
18. MOXIE. http://moxie-gmbh.de/medical-products/. [Accessed 28 February 2015]
19. Staubach P, Groffik A. [Useful tools for documenting urticaria]. Hautarzt 2013; 64:650-655.
20. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128:202-209; e5.
21. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128:567-573.
22. Mathias SD, Crosby RD, Zazzali JL, et al. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2012; 108:20-24.
23. Ye YM, Park JW, Kim SH, et al. Clinical evaluation of the computerized chronic urticaria-specific quality of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol 2012; 37:722-728.
24. Engin B, Uguz F, Yilmaz E, et al. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008; 22:36-40.
25. Grob JJ, Revuz J, Ortonne JP, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152:289-295.
26. Ozkan M, Oflaz SB, Kocaman N, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99:29-33.
27. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154:294-298.
28. Baiardini I, Braido F, Bindslev-Jensen C, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 2011; 66:840-844.
29. Weller K, Church MK, Kalogeromitros D, et al. Chronic spontaneous urticaria: how to assess quality of life in patients receiving treatment. Arch Dermatol 2011; 147:1221-1223.
30. Brzoza Z, Badura-Brzoza K, Mlynek A, et al. Adaptation and initial results of the Polish version of the GA(2)LEN chronic urticaria quality of life questionnaire (CU-Q(2)oL). J Dermatol Sci 2011; 62:36-41.
31. Dias GA, Pires GV, Valle SO, et al. Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire: CU-Q2oL. Allergy 2011; 66:1487-1493.
32. Kocaturk E, Weller K, Martus P, et al. Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity. Acta Dermatovenereol 2012; 92:419-425.
33. Koti I, Weller K, Makris M, et al. Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. Dermatology 2013; 226:371-379.
34. Tavakol M, Mohammadinejad P, Baiardini I, et al. The Persian version of the chronic urticaria quality of life questionnaire: factor analysis, validation, and initial clinical findings. Iran J Allergy Asthma Immunol 2014; 13:278-285.
35. Valero A, Herdman M, Bartra J, et al. Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). J Invest Allergol Clin Immunol 2008; 18:426-432.
36. Prior N, Remor E, Gomez-Traseira C, et al. Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multicentre research project. Health Qual Life Outcomes 2012; 10:82.